ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 598 DKK | -0.08% |
|
+0.08% | +60.24% |
| Apr. 04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
| Mar. 20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
| Sales 2024 * | 693M 98.87M | Sales 2025 * | 1.14B 163M | Capitalization | 37.24B 5.31B |
|---|---|---|---|---|---|
| Net income 2024 * | -358M -51.08M | Net income 2025 * | -254M -36.24M | EV / Sales 2024 * | 49.9 x |
| Net cash position 2024 * | 2.69B 383M | Net cash position 2025 * | 2.77B 396M | EV / Sales 2025 * | 30.2 x |
| P/E ratio 2024 * |
-104
x | P/E ratio 2025 * |
-1,174
x | Employees | 253 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zealand Pharma A/S
More press releases
More news
| 1 day | -0.08% | ||
| 1 week | -2.45% | ||
| Current month | -12.25% | ||
| 1 month | -14.27% | ||
| 3 months | +35.97% | ||
| 6 months | +85.48% | ||
| Current year | +60.24% |
1 week
581.50
609.00
1 month
580.50731.00
Current year
342.20749.00
1 year
212.20749.00
3 years
69.55749.00
5 years
69.55749.00
10 years
58.00749.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 09-12-31 | |
| Director of Finance/CFO | - | 22-10-31 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 19-04-03 |
| Chairman | 69 | 14-12-31 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18-04-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 598 | -0.08% | 153,865 |
| 24-04-17 | 598.5 | -1.07% | 203,665 |
| 24-04-16 | 605 | +1.77% | 181,683 |
| 24-04-15 | 594.5 | +0.85% | 172,894 |
| 24-04-12 | 589.5 | -1.34% | 314,591 |
Delayed Quote Nasdaq Copenhagen, April 18, 2024 at 10:59 am EDT
More quotes
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-05-16
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
598
DKK
Average target price
754.3
DKK
Spread / Average Target
+26.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +60.24% | 5.31B | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- ZEAL Stock
